Study: NCT02577029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg once daily; oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a
Description: 180 mcg; subcutaneous injection once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a
Description: 180 mcg; subcutaneous injection once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a
Description: 180 mcg; subcutaneous injection once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a
Description: 180 mcg; subcutaneous injection once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a
Description: 180 mcg; subcutaneous injection once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a
Description: 180 mcg; subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil
Description: 300 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil
Description: 300 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil
Description: 300 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil
Description: 300 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil
Description: 300 mg once daily; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.